DNA methylation plays a significant role in assuring cell identity, thus potentiating its application in molecular classification of cancers in respect to tissue-origins or clinically and etiologically distinct subtypes. In this study, we optimized our liquid hybridization capture-based bisulfite sequencing (LHC-BS) approach on the gene promoter regions of 11 cell lines. Our results indicated that promoter methylomes could not only cluster cancer cell lines with respect to tissue origins but also differentiate cancer subtypes based on CpG island methylator phenotype (CIMP). Promoter-targeted LHC-BS as means for comprehensive screening and classifying cancer cells with promoter methylomes provided a powerful strategy for further complex clinical studies.
Introduction
As an important regulatory region of a genome, promoter functionality can explain most of the variation in RNA expression (1) . A vast amount of previous knowledge had been gained about the aberrant DNA methylation of promoters frequently occurring in cancers. It was reported that hypomethylation could lead to activation of oncogenes, while hypermethylation of tumor suppressor genes (TSG) was usually associated with transcriptional silencing (2) (3) (4) . Therefore, DNA methylation status of promoters provides clues on tumor progression. Moreover, tissue-specific and cancer-specific differentially methylated regions (DMRs) were frequently discovered in CpG islands (CGIs) and CpG island shores (CGS) (2, (5) (6) (7) (8) that are located at gene promoters. DNA methylation was thereby tightly associated with cell identity and thus might be used as molecular classifier for cancer cells.
Extensive studies had been performed on cancer identification based on molecular markers in order to improve upon existing morphology-based classification schemes (9) (10) (11) (12) . As a stable molecular modification, molecular classification of cancer by promoter methylation can benefit the establishment of tissue-or Technology in Cancer Research & Treatment 2014 March 17. Epub ahead of print cancer-specific profiles, which might further assist the diagnostic work-up of patients with metastatic cancer of unknown origin at the time of initial diagnosis.
Previous studies also indicated that subgroups of cancers might display CpG island methylator phenotype (CIMP) feature (13) (14) (15) (16) . Subsequent studies demonstrated that patients with CIMP tumors exhibited worse survival outcomes and poor prognosis (17, 18) . As majority of the CGIs are located in promoters (19) (20) (21) , cancer subgroups in response to cancer treatments can be identified based on promoter CIMP feature of the cancer, despite a consensus definition of CIMP, screening a number of promoters will be required (15) .
Thereby, high-throughput and high-resolution quantitative technologies are inevitably required for simultaneous and comprehensive quantification of promoter methylomes for many thousands of genes. Due to the improvement of next-generation sequencing technologies, sequencing cost is rapidly decreasing, raising the possibility for generating single-base resolution DNA methylation maps in a large number of cancer specimens. We previously established a liquid hybridization capture-based bisulfite sequencing (LHC-BS) approach and used it for methylation detection of exons (22) . In this study, we customized 150, 407 capture probes that cover 91.8% of the RefSeq gene promoters within human genome, which denotes the upstream 2,200 bp and downstream 500 bp around the transcriptional start sites (TSSs) (23) . Based on a systematic assessment on the performance of this set of probes, we proved the potentiality of promoter-targeted LHC-BS that requires reduced experimental cost and less amount of initial DNA samples in comparison with the previous design (24) . In addition, we generated single-base promoter methylomes for 10 cell lines, including eight cancer cell lines generated from four types of tissues and one pair of model cell lines for ovarian cancer (T29 and T29H). Hierarchical clustering analysis was performed on these 10 cell lines based on the comprehensive promoter methylome sequencing. As a result, we could clearly cluster these 10 cancer cell lines in respect of tissue-origins. We compared our cluster analysis with results using gene expression profiling approach, resulting in high similarity in observed clustering patterns. We also observed some differences, which might be explained by the sensitivity of promoter-targeted LHC-BS in identifying CIMP-associated cancer subtypes. The use of this approach potentiates the molecular classification of different types of cancers as well as subtypes of individual cancer with respect to CIMP. Considering the potential of methylome artifacts induced by tissue culture and the contamination by stromal and inflammatory cells in tumor tissues, further screening a subset of representative promoters might be required to increase the sensitivity for studies on highly heterogeneous tumor tissues.
Materials and Methods

Cell Lines
A lymphoblastoid cell line was generated from a male Han Chinese individual (YH) (22) . One gastric cancer cell line (AGS), one renal cancer cell line (786-O), two bladder cancer cell lines (5637 and T24) were purchased from the American Type Culture Collection (ATCC, Rockville, MD); two lung cancer cell lines (HCC827 and NCl-H1395) were provided by Stem Cell Bank, Chinese Academy of Sciences; another renal cancer cell line OS-RC-2 was from Riken Cell Bank (Tsukuba, Japan). One gastric cancer cell line (BGC-823) was obtained from Beijing Tumor Hospital (Beijing, China). Two human ovarian cancer model cell lines (T29 and T29H) were provided by Beijing Institute of Life Science, Chinese Academy of Science (Beijing, China). Cells were cultured according to the supplier's recommendations.
Probe Design for Promoter-targeted LHC-BS
Promoters are defined as the regions crossing the upstream 2,200 bp and downstream 500 bp of the transcriptional start site. A complete set of 34,163 genes located in the 22 autosomes and the XY sex chromosomes were prepared based on the RefSeq gene files (http://genome.ucsc.edu/, hg19). The promoters overlapped with each other were merged to form a large region, resulting in 20,882 merged candidate regions ranging from 2,700 to 8,864 bp with the average length of 2858 bp. The capture probes were designed and synthesized by Roche Nimblegen Incorporation, consisted of 150, 407 oligonucleotides. The information on the probes (start and end positions of the probe sequences in the human genome), which can reproducibly capture target DNA is provided in the Supplementary Table S1 .
Library Construction, Liquid Hybridization-based Target Capture and Bisulfite Sequencing
Genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen). 1 µg of genomic DNA was fragmented into approximately 200-300 bp using a Covarias sonication system (Covarias). After purification, the fragmented fractions were treated with a mix of T4 DNA polymerase, Klenow Fragment and T4 polynucleotide kinase to repair blunt and phosphorylate ends. The blunt DNA fragments were subsequently 3 adenylated using Klenow Fragment (3-5 exo-) and then ligated by T4 DNA Ligase to adapters that were synthesized with 5-methylcytosine instead of 5-cytosine and contain index sequences inside. After each step, the reaction products were purified using QIAquick PCR purification kit (Qiagen). The constructed libraries were quantified using a Qubit fluorometer with Quant-iT dsDNA HS Assay Kit (Invitrogen). The liquid hybridization capture procedure was performed as follows. Briefly, 200 ng DNA from each of five adapterligated libraries were pooled together and then we obtained two adapter-ligated pooling libraries. 10 µg human Cot-1 DNA and 1 nmol of adapter complementary DNA oligos were added and subsequently were dried using a SpeedVac (Eppendorf) at 608C. After that, the mixture was denatured at 958C for 10 min in a final reaction volume of 10.5 µl consist of 7.5 µl 2X SC Hybridization Buffer and 3 µl SC Hybridization Component A. After centrifugation, 4.5 µl of designed probes were added and the mixture was hybridized in a thermal cycler at 478C for 72 hours with the lid heated at 578C. After hybridization, the biotinylated probes that had bound the target DNA were captured using 100 µl of Dynabeads ® M-280 Streptavidin (Invitrogen), which had been pre-washed two times with a total of 400 µl Streptavidin Dynabead Binging and Washing Buffer. The capture program was incubated at 478C for 45 min in a thermal cycler with the lid heated at 578C and vortexing for 3 s at 15 min intervals. Discarded the unbounded fractions and washed the collected DNA-probe-beads complex with 100 µl of 478C pre-warmed 1X Wash Buffer I for one time and with a total of 400 µl of 478C pre-warmed 1X Stringent Wash Buffer I for two times with the incubations of 478C for 5 min. After discarded the supernatant, the collected beads complex was washed again with 200 µl of 1X Wash Buffer I, 1X Wash Buffer II and 1X Wash Buffer III respectively. The entire hybridization and wash buffers in the experiment was purchased from Roche NimbleGen (SeqCap EZ Hybridization and Wash Kits). Finally, the captured DNA was eluted in 50 µl of 10 M NaOH with incubation at room temperature for 10 min. The supernatant was transferred into a new tube and neutralized with 50 µl of 10 M HAc and then purified using MiniElute PCR purification Kit (Qiagen).
For bisulfite conversion, 200 ng of unmethylated lambda DNA was added into each captured product as carriers and ZYMO EZ DNA Methylation-Gold Kit™ (ZYMO) was employed to convert unmethylated cytosine into uracil according to the instructions. After purification, PCR was carried out in a final reaction volume of 50 µl consisting of 20 µl converted products, 4 µl 2.5 mM dNTP, 5 µl 10X buffer, 0.5 µl JumpStart™ Taq DNA Polymerase (SIGMA), 1 µl PCR primers 1.0, 1 µl PCR index primers and 18.5 µl water. The following thermal cycling program was 948C 1 min, 15 cycles of 948C 10 s, 588C 45 s, 728C 30 s then prolong at 728C for 5 min and hold at 128C. The PCR products were purified using AMPure beads (Agencourt), quantified by the Bioanalyzer analysis system (Agilent) and real-time PCR assay and then analyzed using Illumina Hiseq2000.
RNA Preparation and RNA-seq Libraries Construction
Total RNA were prepared using TRIzol ® Reagent (Invitrogen) and digested with RNase-free DNase I (Ambion).
RNA-sequencing library was constructed as we previously described (25) . Briefly, the poly(A)-containing mRNA was purified using Oligo(dT) Beads (Illumina) from 20 µg of total RNA, fragmented and converted into double-stranded cDNA. Then, the resulting cDNA was subjected to bluntending, dA addition to the 3 end and adapter ligation. The adapter-ligated fragments were size selected (200 6 20 bp) using 2% TAE-Certified Low-Range Ultra Agarose (Bio-Rad). After purification, fifteen rounds of PCR amplification were performed to enrich the adapter-ligated cDNA libraries. Finally, after detection on an Agilent Technologies 2100 Bioanalyser using the Agilent DNA 1000 chip kit and quantification on a StepOne plus qPCR, the cDNA library products were sequenced using the Illumina Hiseq2000. Gene expression levels were measured by the Reads Per Kilobase of transcript per Million reads (RPKM) algorithm.
CIMP Feature Validation by Quantitative Methylationspecific PCR (QMSP)
Methylation-specific PCR primers were designed by the online MethPrimer software (www.urogene.org/methprimer/ index.html). Primer information is listed in Supplementary  Table S2 . Genomic DNA was converted by ZYMO EZ DNA Methylation-Gold Kit (ZYMO). ACTB was used as an internal reference gene for normalization during fluorescencebased real-time PCR analysis. The relative methylation status for each gene was determined by comparative Ct method and then multiplied by 1000 for easier tabulation (relative methylation levels 5 2 average Ct (ACTB)-average Ct (gene) 3 1000). All results were got from three independent experiments and the amplification was performed in triplicates.
5-Aza-dC Treatments and Cell Proliferation Assay
The iCELLigence system (ACEA Biosciences) was used to evaluate cell proliferation with or without 5-Aza-dC treatment, respectively. HCC827 and NCI-H1395 cells were cultured with RPMI-1640 medium containing 10% fetal bovine inactivated serum (FBS). After growing to about 75% confluence, cells were harvested and counted. About 8 3 10 4 cells of HCC827 and NCI-H1395 were diluted with 2.4 ml of complete culture medium respectively. 5-Aza-dC containing medium was prepared by adding 6 µl of 5-Aza-dC (2 mM) into 800 µl of complete culture medium. After this, 150 µl of 5-Aza-dC containing medium or complete culture medium were added into each well of E-Plate L8 (ACEA Biosciences) for background impedance measurement. Subsequently, 300 µl of previously diluted cells (about 10 4 cells) were added into the wells containing 5-Aza-dC medium or complete culture medium. Cells proliferation with or without 5-Aza-dC (5 µM) treatment was monitored in triplicates at 24 hour intervals for 6 days. 
Computational Processing of the LHC-BS Data
After removing the adapter sequences and filtering out the low quality reads (reads containing bases N or reads containing the number of bases with base quality less than 20 over half of the whole bases within the read), the bisulfite sequencing reads were directly aligned to the human reference genome (UCSC hg19) using BSMAP 2.73 with default parameters (26) , which combines genome hashing and bitwise masking to achieve fast and accurate bisulfite mapping. DNA methylation measurement/level of a specific cytosine was then calculated as the number of reads supporting methylation divided by the total number of reads covering that cytosine. CGIs were defined as regions greater than 200 bp with a GC fraction greater than 0.5 and an observedto-expected ratio of CpG greater than 0.65 as annotated in UCSC genome browser. CpG island shores were defined as regions of the up-or down-stream 2 kb adjacent to CGIs. Pearson/Spearman correlations were used to analyze methylation levels of two experimental replicates and the relationships between promoters methylation and associated gene expresses. Chi-square test was used to estimate differential methylation levels of promoters between paired samples. R packed pvclust was used for assessing the uncertainty in hierchical cluster analysis. Pvclust performed hierarchical cluster analysis via function hclust in R, and for each cluster in hierarchical clustering, quantities called p values were calculated via multiscale bottstrap resampling. P value indicated stability of the cluster supported by the data.
Data Accession
We have previously generated RNA-seq data for AGS and BGC-823 with GEO accession numbers of GSM1056528 and GSM1056529, for 5637 and T24 with NCBI SRA accession number SRA052960, respectively. Affymetrix Human Genome U133 Plus 2.0 Array data of HCC827 and NCI-H1395 were taken from GSM887060 and GSM887361, respectively. The raw sequence data as well as the DNA methylation estimation record of every single cytosine for the cell lines used in this study are deposited into National Center for Biotechnology Information Gene Expression Omnibus database, with NCBI SRA accession number GSE44866.
Results and Discussion
Establishment and Assessment of Promoter-targeted LHC-BS
To establish promoter-targeted LHC-BS, we adopted the definition of promoter regions in (23), i.e., the upstream 2,200 bp and the downstream 500 bp regions crossing the transcriptional start site (TSS) ( Figure 1A) . In sum, 150,407 capture probes were successfully designed with a total length of 54. 5 Table S1 ). 66.6% of the targeted promoters contain a CGI inside, while 69.0% of these CGIs shores were covered as well. As a result, 47.7% of the total CGIs and 35.8% CGSs in the genome were covered in current design.
Applying the promoter-targeted LHC-BS, we first analyzed a lymphoblastoid cell line (YH) (26) (27) (28) . Two independent replicates of libraries were prepared with each requiring about 2 µg initial genomic DNA, generating 2.3 G and 8.9 G raw sequence data, respectively. 72.2% and 70.1% of the total reads were uniquely mapped to the Watson strand of the hg19 reference, respectively ( Supplementary Table S3 ), resulting in an average of ~32X and ~124X sequencing depth per CpG (based on the mapping data). Furthermore, more than 80% of the non-redundant and uniquely mapped reads were aligned to the target regions, suggesting for a high efficiency of the capture reactions ( Figure 1B and Supplementary Table  S3 ). By randomly extracting 2.3 G data out of the 8.9 G raw sequence data from the second YH library, we assessed the technical reproducibility between the two technical replicates by Pearsons correlation. As a result, a high coefficient (R 5 0.974) was observed ( Figure 1C ). As we have generated the methylome of the same cell line using whole genome bisulfite sequencing (WGBS) method (26), we thus selected ~320 K CpG sites with 5X sequencing depth shared by both the LHC-BS and the WGBS methods to assess the validity of here developed sequencing method. As a result, the correlation coefficients were up to 0.965 and 0.973 between the two replicates of LHC-BS data and WGBS data using Pearson's correlation analysis ( Supplementary Figure 1) , which indicated the accuracy of LHC-BS to identify methylation status of promoter regions. However, similar to WGBS method, LHC-BS method could not distinguish 5-mC from the recently discovered three new modification of cytosine (5-hydroxymethylcytosine (5-hmC) (29, 30) , 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) (31) because 5-hmC behaves similarly to 5-mC but 5-fC and 5-caC behave similarly to cytosine during bisulfite conversion treatment. This shortage should be especially considered when applying LHC-BS method in stem cell or brain tissue studies. Furthermore, we combined the two replicates of YH sequencing data to evaluate the amount of raw sequence data that is required by this technology. As a result, a saturation of cytosine coverage was observed with around 20% of the total 11.2 Gbp data, meanwhile 20X sequencing depth on average can be achieved ( Figure 1D ). With sequencing data increasing, we observed that although the coverage of targeted regions remained the same, the average sequencing depth was gradually increased, and 40% of the total data might achieve about 40X coverage ( Figure 1D ). These results indicated that LHC-BS methods could cover almost all of the annotated promoters with specified required sequencing depth. Thus researchers could employ it in many fields that involved promotermethylation, such as exploring relationships or mechanisms of promoter methylation and gene expression in disease with multiple clinical samples.
We further used the promoter-targeted LHC-BS approach to study 10 cell lines, including eight cancer cell lines and a pair of human ovarian cancer model cell lines (T29 and T29H) (see Methods). In contrast to a previous strategy using multiple capture reactions for one library construction per sample (24), we applied a sample pooling strategy prior to liquid hybridization capture as proposed by Agilent Technologies that can improve efficiency and cost-effectiveness of targeted genomic enrichment (32) . We pooled five cell lines for one capture reaction after index adapter ligation and this meant that five samples were constructed as one final library and then sequenced on Illumina Hiseq2000 Analyser. As a result, consistent with that of YH cell lines, it also presented well probes success-capture rate ( Supplementary Table S3 ). Thus, the promotertargeted LHC-BS approach we described here represented a means for profiling of promoter methylomes with better efficiency and cost-effectiveness of target enrichment and lower amount of initial DNA samples, which endowed the potential possibility for researches using multiple clinical samples. (D) Simultaneous evaluation of targeted regional coverage (upper line) and mean sequencing depth (lower line) with increasing required raw sequence data. A total of 11.2 Gbp raw data was randomly extracted for analyses and 20% of them (about 2 Gbp) could cover more than 90% targeted regions and achieve 20X mean coverage depth.
Technology in Cancer Research & Treatment 2014 March 17. Epub ahead of print
Clustering of Cancer Cell Lines Based on Promoter DNA Methylomes
To test whether the methylation status of promoter regions could be used for cancer classification with respect to tissue origin or benign versus aggressive behaviour, we performed a "Pvclust" algorithm (33) of unsupervised hierarchical clustering analysis on the average methylation levels of all promoters (Figure 2A ) or all CGI located promoters (Figure 2B ) in 10 cell lines. As a result, three pairs of cell lines with each pair derived from the same type of tissue (bladder cell 5637 and T24, renal cell 786-O and OS-RC-2, ovarian epithelial cell T29 and T29H) were constantly classified into the same cluster. Other two pairs (gastric cell AGS and BGC-823, lung cell HCC-827 and HCI-H1395) were separated but very close to each other. T29H was generated by transforming the ovarian epithelial cell line T29 with an additional oncogenic rasV12 allele (34) . The RAS signalling pathway then spurred the activation of DNA methyltransferases (DNMT) activation, leading to the suppression of TSGs (35) . This result implied that although aberrant DNA methylation occurred in tumors, the cancer cell might still harbor its tissue-specific promoter methylome. Our results were in agreement with a previous study using microarray-based method, which showed the cancer-specific differentially methylated regions (cDMRs) corresponded largely to the same regions that showed DNA methylation variation among tissue-specific DMRs (tDMRs) (19) . This study also suggested that most tissue-specific DNA methylation occurred in 'CpG island shores'. As our promoter-capture probes covered most of the promoter CGSs (69.0%) and enabled detection of DNA methylation status for every single CpG within the promoter regions, thus it could serve as a better approach for organ-and cancer-specific classification.
On the other hand, gene expression profiling has already been considered as a meaningful marker for molecular classification of cancers (9, 12) . To compare the outcomes of two types of molecular classification, we obtained RNA-seq data of eight out of the 10 cell lines and Affymetrix Human Genome U133 Plus 2.0 Array data of another two cell lines (See Methods) and then performed hierarchical clustering analysis on the gene expression profiles. As a result, we obtained almost the same tree structure as the DNA methylation profiling presented ( Figure 2C ). However, the two gastric cancer cell lines (AGS and BGC-823) as well as the two lung cancer cell lines (HCC827 and NCI-H1395) were clustered into one cluster, respectively, in a relatively low height ( Figure 2C ). As the cluster height in "Pvclust" algorithm (33) represents the divergence between two samples in one cluster, these results indicated a more similar mRNA expression profiles than promoter methylation profiles. Thereby, the above results demonstrated a similar potential of using promoter methylome for classifying cells originated from different tissue-origins in comparison with using gene expression profiles. However, promoter methylation might be more sensitive to differentiate two cell lines from same tissue-origins, thus raising the possibility of identifying cancer subgroups which was beyond the capability of gene expression profiles.
CIMP Subtype of Cancer Cell Line Identified by Promoter Methylation Profiles
In the above results, considerable divergence in clustering promoter methylation levels for the two gastric cancer cell lines (AGS and BGC-823) and the two lung cancer cell lines (HCC-827 and HCI-H1395) were showed despite the clustering analyses, suggesting for their tissue-specificity ( Figures   2A and 2B) . Previously, the concept of the CpG island methylator phenotype (CIMP) was raised to describe the clinical relevant cancer subtypes that are associated with more extensive methylation (13) (14) (15) (16) . Patients with CIMP-associated cancers subtypes exhibited worse survival outcomes and poor prognosis. However, conventional assessment of gene expression profiles is not able to distinguish such cancer subtypes (17, 18, (36) (37) (38) (39) (40) . In relation with our results, Zouridis and colleagues identified a subset of gastric cancers including AGS cell line showing CIMP features (17) . Another study revealed distinct intrinsic resistance to drug treatment between AGS and BGC-823 cell lines (41) . These results led us to speculate that AGS and BGC-823 cell lines might belong to distinct subtypes in respect of CIMP feature. By applying a chi-square test, we screened out 14,001 promoters (8,568 CGI promoters and 5,433 non-CGI promoters) with significantly differential methylation (p , 0.01, FDR , 0.01) between AGS and BGC-823 cell lines. 6,968 (81%) of the CGI promoters and 5,066 (93%) of the non-CGI promoters were hypermethylated in AGS cells, indicating distinct methylation patterns for these two cell lines ( Figures 3A-3D) . Notably, the previously identified methylation markers for CIMP gastric cancers (CDKN2A, MLH1, RARB, and two CpG islands MINT1 and MINT2) (13, 42, 43) were all hypermethylated in AGS cells, confirming the CIMP-feature of AGS cells. In contrast, these marker genes were all hypomethylated in BGC-823 cells, suggesting BGC-823 cells belonged to the non-CIMP subtype ( Figure 3A) . Previously, the model describing that hypermethylation of CGI promoters is widely associated with transcriptional silencing has been highlighted, especially in the case of tumor suppressor genes (TSGs) (2) (3) (4) . We thus further looked into the promoter methylation and gene expression status of genes that were significantly differentiated for promoter methylation between AGS and BGC-823 cell lines. Firstly, the silent genes among all differentially methylated genes in both AGS and BGC-823 cell lines were analyzed. As Figure 4A indicated, most of the promoters of these silent genes were relatively hypermethylated in AGS cell line. In contrast, a large subset of the promoters of these silent genes remained hypomethylated in BGC-823 cells, which indicated that silencing of these genes was not directly due to promoter hypermethylation. Different repression mechanisms might be involved in inhibiting the transcription of these genes in non-CIMP BGC-823 cells. For example, genes can be repressed by Polycomb-repressive complex (PRC) and the associated H3K27me3 marks (44) . Secondly, we also analyzed the expressed genes. By dividing the expressed genes into more expressed (upper quartile of RPKM value), less expressed (lower quartile of RPKM value) and median expressed subgroups in both of the two cell lines, we found that most of these differentially methylated genes were hypermethylated in AGS cells for all of the three subgroups. In contrast, the expression levels for these three groups of genes were similarly distributed between these two cell lines ( Supplementary  Figure 2) . These results proved our hypothesis and indicated that gene expression profiles could not be used to distinguish cancers with CIMP subtypes. Furthermore, the alteration of promoter methylation between AGS cells and BGC-823 cells might exert little effects on transcription activities, which is also in agreement with previous studies (13, 42, 43) .
Previous studies also revealed CIMP-associated subtypes for lung adenocarcinomas (18) . Through the same chisquare test, we observed 15,465 significantly differentially methylated promoters (10,231 CGI promoters and 5,234 non-CGI promoters). Similarly, majority (75%) of the CGI promoters were hypermethylated in HCC827 cell line in comparison with NCI-H1395 cell line ( Supplementary Figures 3A and 3B) , despite the non-CGI promoter didn't present any divergence (50% hypermethylated) ( Supplementary   Figures 3C and 3D) . These results suggested that HCC827 and NCI-H1395 cell lines might be classified into different CIMP-associated cancer subtypes, although a subset of the CGI contained promoters were also hypermethylated in NCI-H1395 cell line (Supplementary Figure 3A and 3B) . We then interrogated five methylation markers of CIMP lung adenocarcinomas (CCNA1, ACAN, GFRA1, EDARADD, and CDKN2A) (18) in the two cancer cell lines to further examine this possibility. As a result, four of the five methylation markers were hypermethylated in HCC827 cell line (Supplementary Figures 3A) . We then applied BS-qPCR to test the methylation levels of CDKN2A and RAR-beta genes in AGS and BGC-823 cells, and ACAN, CCNA1, and GFRA1 genes in HCC827 and NCI-H1395 cells. The results confirmed the hypermethylation status of these genes in AGS and HCC827 cells in comparison with BGC-823 and NCI-H1395 cell, respectively, proving the accuracy of our LHC-BS method ( Figures 4B and 4C) . Thus, as HCC827 showed similar high CGI-methylation phenotypes, we speculated that HCC827 cell line might also contain CIMP feature and originate from a CIMP cancer subgroups that is different from NCI-H1395 cell line.
To confirm the above speculation on HCC827 cell line, we performed functional analysis on the two lung adenocarcinomas cell lines. As previous studies indicated that CIMP cell lines displayed sensitivity to 5-Aza-2-deoxycytidine (5-Aza-dC, DAC) (17), a clinically approved demethylating drug, we performed DAC treatment on HCC827 and NCI-H1395 cell lines and measured their proliferation using a real-time cell analyzer (RTCA) iCELLigence system. Our results indicated that the cellular viability of HCC827 was However, the viability of NCI-H1395 was barely affected ( Figure 4D) . Therefore, HCC827 cell line is sensitive to DAC therapy, similar to the CIMP cancer subtypes identified previously (17) .
Based on our results above, we concluded that the pair of AGS and BGC-823 or HCC827 and NCI-H1395 cell lines belong to CIMP-associated or non-CIMP-associated subtypes, respectively. These cell lines can serve as models in studying CIMP of gastric or lung cancer, respectively, which can be potentially used in cancer treatment studies, such as therapeutic targeting and drug response. Therefore, although a variety of methods for studying DNA methylation are available (15) , LHC-BS might represent a comprehensive approach for CIMP identification due to its high-resolution and whole promoter coverage. Furthermore, patients with CIMP features might be identified by performing clustering analysis and analyzing reported CIMP markers based on this method. However, other factors, such as age-related and individual-specific methylation was reported in several studies (15, 45) , might confuse the identification of CIMP subtypes. Currently it is difficult to set up some criteria in defining CIMP feature based on LHC-BS data with previous established CIMP cell lines. Large scale of studies on quantitatively investigating methylation status of CGI-promoters in cancer subtypes might be needed to search for more CIMP markers by filtering out noise information in the future.
Conclusion
The promoter-targeted LHC-BS approach provides an unbiased capture of promoter regions in a genome, ensuring a most comprehensive detection of cytosine methylation. In present study, we have demonstrated the feasibility of using this approach to determine promoter methylome in singlebase resolution, and highlight the application of this approach in molecular classification of cancer cell lines originated from different tissue-origins and CIMP subtypes. In future application in classifying highly heterogeneous tumor tissues, the potential of methylome artifacts induced by tissue culture and the contamination by stromal and inflammatory cells in tumor tissues should be considered. To increase the sensitivity, the design of the liquid hybridization captureprobes can be further optimized by incorporating cancer-or tissue-specific DMR regions.
